Compositions and kits for treating influenza

US7981930B2 · kind B2 · utility

Assignee

• Adamas Pharmaceuticals, Inc. · US

Inventors

• Jack Nguyen · San Clemente, US
• Gregory T. Went · Mill Valley, US
• Paul Spence · Knoxville, US
• Timothy J. Fultz · Martinez, US
• David Chernoff · San Rafael, US
• Terry L. Burkoth · Palo Alto, US
• Rowan Chapman · Menlo Park, US
• Mickey S. Urdea · San Francisco, US

Key dates

• Filing date: Feb 29, 2008
• Grant date: Jul 19, 2011
• Expiry date: Aug 5, 2029

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Kits comprising an M2 inhibitor selected from amantadine and rimantadine; ribavirin, and a neuraminidase inhibitor (NAi) in an amount that is antivirally effective in the combination, an oral dosage form containing 75-250 mg of the M2 inhibitor, an oral dosage form comprising 100-400 mg of ribavirin and a neuraminidase inhibitor are provided for the treatment of influenza. Some embodiments of the kits comprise an oral dosage form containing 75-250 mg of the M2 inhibitor, an oral dosage form comprising 100-400 mg of ribavirin, and a neuraminidase inhibitor.